Dr. Gregory Stock, a biotech entrepreneur, academic scientist, bioethicist, best-selling author and public communicator is a leading authority on the broad impacts of genomic and advanced digital-health technologies. He is a professor at the Mt. Sinai School of Medicine in New York where he co-directs the Harris Center for Precision Wellness and is working on the foundations of nextgen wellness and healthcare. Previously, he founded the influential Program on Medicine, Technology and Society at UCLA’s School of Medicine and served as its director for ten years while leading a broad effort to explore critical technologies poised to impact humanity’s future and reshape medical science and healthcare.
Dr. Stock is a strong advocate for aggressive biomedical research and cautious regulatory policy. He has co-founded and led two biotech companies. In 2003, he co-founded Signum Biosciences, a Princeton University spinout that developed a new class of anti-inflammatory signal-transduction molecules to combat neurodegeneration and served as the CEO for 7 years directing efforts to develop a therapeutic for Alzheimer’s and related anti-inflammatory cosmeceuticals and nutraceuticals. In 2010, he co-founded Ecoeos, a personalized-health company that created the first genetic test to gauge individualized susceptibility to mercury toxicity, and served as CEO and CSO of Ecoeos until 2014.
Dr. Stock has been an invited speaker to diverse academic, government and business conferences. He sits on the editorial boards of The Journal of Evolution and Technology, and Rejuvenation Research. He has been profiled in the Wall Street Journal, New York Times, MIT Tech Review and Lancet. He makes regular appearances on television and radio, including CNN, PBS, NPR, Bloomberg, and the BBC and has been in dozens of one-on-one healthcare policy debates with Francis Fukuyama, Jeremy Rifkin, Leon Kass, Daniel Callahan, Ray Kurzweil, Bill McKibben, George Annas and other prominent figures.
Dr. Stock’s book, Redesigning Humans: Our Inevitable Genetic Future with Houghton Mifflin won the Kistler Book Prize for Science books and was nominated for a Wired Rave Award. Among his other books are Engineering The Human Germline: An Exploration of the Science and Ethics of Altering the Genes We Pass to Our Children with Oxford University Press, Metaman: The Merging of Humans and Machines into a Global Superorganism with Simon & Schuster, and his best seller, The Book of Questions with Workman Press, which has sold 2 1 /2 million copies and been translated into 18 languages. It is now nearing 100 printings. Sequels to that book include The Book of Questions: Business, Politics, and Ethics, The Book of Questions: Love and Sex, The Kids’ Book of Questions, and The Book of Questions: Power, Principles, and Purpose. Stock is now working on a new book, On the Cusp: The Promise of Nextgen Healthcare, describing the coming disruptive, data-and-technology-driven transformation of healthcare.
Stock serves on the California Advisory Committee on Stem Cells and Reproductive Cloning, and on the Board of Directors of Signum Biosciences, Nutralogix, and Napo Pharmaceuticals. He has a PhD in Biophysics from Johns Hopkins University and an MBA from Harvard Business School.